In advanced-stage PCA, the role of HDAC6 in regulating androgen receptor (AR) hypersensitivity, occurring mainly through Hsp90 acetylation/deacetylation [40], underscores the therapeutic potential of dual HDAC6/Hsp90 inhibitors. This evidence concerns the gene AR and posterior cortical atrophy.